



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Thursday April 16, 2026

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
TLXAP	SHARE RIGHTS	79,750	23/02/2026
New class - code to be confirmed	SHARE RIGHTS US	384,500	23/02/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

16/4/2026



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

does not have an existing ASX security code ("new class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

TLXAP : SHARE RIGHTS

Date the +securities the subject of this notification were issued

23/2/2026

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix Equity Incentive Plan Rules (available at <https://ir.telixpharma.com/governance/documents-charters>) and the Remuneration report within the Telix 2025 and 2024 Annual Reports (available at <https://ir.telixpharma/reports>).

Any other information the entity wishes to provide about the +securities the subject of this notification

A total of 71,000 zero-priced retention share rights were issued in equal tranches:

- tranche 1, restricted to 1 November 2028 (3 year retention), subject to testing on 1 November 2028;
- tranche 2, restricted to 1 November 2029 (4 year retention), subject to testing on 1 November 2029.

Exercise period: 2 years from vesting date.

In addition, 8,750 zero-priced performance share rights were granted and are immediately exercisable based on satisfaction of performance condition for the period ended 31 December 2025.

Issue details

Number of +securities

79,750



Part 3C - number and type of +securities the subject of this notification (new class)

ASX +security code

New class - code to be confirmed

+Security description

SHARE RIGHTS US

+Security type

Other

ISIN code**Date the +securities the subject of this notification were issued**

23/2/2026

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Refer to Telix's Remuneration report within its 2025 Annual Report, including Item 6.B "Compensation" of the Form 20-F (available at <https://ir.telixpharma/reports>).

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to the Telix Equity Incentive Plan Rules (available at <https://ir.telixpharma/governance/documents-charters>).

Any other information the entity wishes to provide about the +securities the subject of this notification

Retention share rights granted to certain US based Telix employees, to be delivered as American Depositary Shares to US domiciled employees.

A total of 384,500 zero-priced retention share rights granted in two equal tranches:

- tranche 1, restricted to 1 November 2028 (3 year retention), subject to testing on 1 November 2028;
- tranche 2, restricted to 1 November 2029 (4 year retention), subject to testing on 1 November 2029.

Exercise period: automatic exercise at the end of the restriction period.

Issue details

Number of +securities

384,500



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	339,113,888

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAY : DEFERRED SHARE RIGHTS	66,140
TLXAX : DEFERRED SHARE RIGHTS EX-US	60,528
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,289,754
TLXAO : SHARE APPRECIATION RIGHTS	13,591,133
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	175,000
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	9,450
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	4,319,130
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000
New class - code to be confirmed : SHARE RIGHTS US	384,500



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13